Herceptin® (Trastuzumab) is the only FDA-approved therapeutic for HER2 protein overexpressing metastatic breast cancer. Herceptin is a therapy for women with metastatic breast cancer whose tumors have too much HER2 protein. For patients with this disease, Herceptin is approved for first-line use in combination with paclitaxel, and as a single agent for those who have received one or more chemotherapy regimens.

Herceptin is not chemotherapy. It is a monoclonal antibody (sometimes called biologic therapy).
– Antibodies are part of the body’s normal defense against bacteria, viruses, and abnormal cells such as cancer cells.
– Monoclonal antibodies are mass-produced in a laboratory. Their name comes from the fact that they are identical and produced from a single cell (clones).

Therapy with monoclonal antibodies is generally a more targeted form of therapy than chemotherapy.

Important Safety Information
Herceptin administration can result in the development of certain heart problems, including congestive heart failure. Severe allergic reactions, infusion reactions, and lung problems have been observed. Rarely, these have been fatal.



Leave a Reply